Outcomes of patients treated through the Canadian Fabry disease initiative

Molecular Genetics and Metabolism

Volumn 111, Issue 4, 2014, Pages 499-506

  Sirrs, S M ^a   Bichet, D G ^b   Casey, R ^c   Clarke, J T R ^d   Lemoine, K ^e   Doucette, S ^f   West, M L ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e Capital District Health Authority   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Agalsidase; Enzyme replacement therapy; Fabry disease; Outcomes

Indexed keywords

ACETYLSALICYLIC ACID; AGALSIDASE ALFA; AGALSIDASE BETA; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ALPHA GALACTOSIDASE; ISOENZYME;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADIAN FABRY DISEASE INITIATIVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; END STAGE RENAL DISEASE; ENZYME REPLACEMENT; EVIDENCE BASED PRACTICE; FABRY DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; BIOASSAY; CANADA; CARDIOVASCULAR DISEASES; COMPLICATION; KAPLAN MEIER METHOD; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ALPHA-GALACTOSIDASE; CANADA; CARDIOVASCULAR DISEASES; COHORT STUDIES; ENDPOINT DETERMINATION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897573302     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.01.014     Document Type: Article

References (36)

1. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 2003, 138:338-346.
2. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized, controlled trial. JAMA 2001, 285:2743-2749.
3. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alfa-galactosidase: a replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345:9-16.
4. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitley C.B., McDonald M., Finkel R., Packman S., Bichet D.G., Warnock D.G., Desnick R.J. Agalsidase-beta therapy for advanced Fabry disease. Ann. Intern. Med. 2007, 146:77-86.
5. Vedder A.C., Linthorst G.E., Houge G., Groener J.E.M., Ormel E.E., Bouma B.J., Aerts J.M.F.G., Hirth A., Hollak C.E.M. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg/kg. PLoS ONE 2007, 7:e598.
6. Mehta A., Ricca R., Widmer U., Dehout F., de Lorenzo A.G., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 2004, 34:236-242.
7. Eng C.M., Fletcher J., Wilcox W.R., Waldek S., Scott C.R., Sillence D.O., Breunig F., Charrow J., Germain D.P., Nicholls K., Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J. Inherit. Metab. Dis. 2007, 30:184-192.
8. Canadian Expert Drug Advisory Committee CEDAC final recommendation on reconsideration and reasons for recommendation agalsidase alfa (Accessed August 26 2013). http://www.cadth.ca/media/cdr/complete/cdr_complete_Replagal_2004Nov24.pdf.
9. Canadian Expert Drug Advisory Committee CEDAC final recommendation and reasons for recommendation agalsidase beta resubmission (Accessed August 26 2013). http://www.cadth.ca/media/cdr/complete/cdr_complete_Fabrazyme_Resubmission_may2005.pdf.
10. El Dib R.P., Nascimento P., Pastores G.M. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Libr. 2013, 2:1-64.
11. Tahir H., Jackson L.L., Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase beta. J. Am. Soc. Nephrol. 2007, 18:2609-2617.
12. Terryn W., Cochat P., Froissart R R., Ortiz A., Pirson Y., Poppe B., Serra A., Van Biesen W., Vanholder R., Wanner C. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol. Dial. Transplant. 2013, 28:505-517.
13. Sirrs S., Clarke J.T.R., Bichet D.G., Casey R., Lemoine K., Flowerdew G., Sinasac D.S., West M.L. Baseline characteristics of subjects enrolled in the Canadian Fabry disease initiative. Mol. Genet. Metab. 2010, 99:367-373.
14. Garman S., Garboczi D.N. The molecular defect leading to Fabry disease: structure of human α-galactosidase. J. Mol. Biol. 2004, 337:319-335.
15. West M.L., LeMoine K., Simms C., Dyack S. Cross-sectional analysis of renal disease in the Nova Scotia Fabry disease kindred. J. Am. Soc. Nephrol. 2002, 13:517A.
16. West M., LeMoine K., McKillup R., Harnett J. Renal transplantation in the Nova Scotia Fabry disease kindred. Acta Paediatr. 2002, 19:133.
17. West M.L., Dyack S., Riddell C., LeMoine K., Camfield C., Camfield P. A Nova Scotia kindred with Fabry disease. Amer. J. Hum. Gen. 2002, 71:418.
18. West M.L., Casey J.T.R.Clarke, Iwanochko R.M., Moore D.F., Sirrs S.M. Canadian Fabry disease Treatment Guidelines 2012 (Accessed August 26 2012). http://www.garrod.ca/wp-content/uploads/Canadian-Fabry%20Disease-Treatment-Guidelines-2012.pdf.
19. Mehta A., Clarke J.T.R., Giugliani R., Elliott P., Linhart A., Beck M., Sunder-Plassmann G. Natural history of Fabry disease: changing patterns and causes of death in FOS - Fabry Outcomes Survey. J. Med Genet. 2009, 46:548-552. on behalf of the FOS investigators.
20. Hughes D.A., Romero M.A., Hollak C.E.M., Giugliani R., Deegan P.B. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS-the Fabry outcome survey. Mol. Genet. Metab. 2011, 103:207-214.
21. Mehta A., Beck M., Elliott P., Giugliani R., Linhart A., Sunder-Plassmann G., Schiffmann R., Barbey F., Ries M., Clarke J.T.R. Enzyme replacement therapy with agalsidase alfa in subjects with Fabry's disease: an analysis of registry data. Lancet 2009, 274:1986-1996. on behalf of the Fabry Outcome Survey Investigators.
22. Sims K., Politei J., Banikazemi M., Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke 2009, 40:788-794.
23. Salviati A., Burlina A.P., Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult subjects, enzymereplacement, and support therapy. Neurol. Sci. 2010, 31:299-306.
24. Rombach S.M., Twickler T.B., Aerts J.M.F.G., Linthorst G.E., Wijburg F.A., Hollak C.E.M. Vasculopathy in subjects with Fabry disease: current controversies and research directions. Mol. Genet. Metab. 2010, 99:99-108.
25. Lysosomal Storage Diseases Expert Advisory Group Adult Fabry disease standard operating procedures (Accessed August 26 2013). http://www.specialisedservices.nhs.uk/document/guidelines-anderson-fabry-disease.
26. Anonymous Guidelines for the treatment of Fabry disease through the life saving drugs program (Accessed August 26 2013). http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-info/$File/Fabry-Guidelines-29-July-2013.doc
27. Schiffmann R., Warnock D.G., Banikazemi M., Bultas J., Linthorst G.E., Packman S., Sorensen S.A., Wilcox W.R., Desnick R.J. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 2009, 24:2102-2111.
28. Rombach S.M., Smid B.E., Bouwman M.G., Linthorst G.E., Dijkgraaf M.G., Hollak C.E. Enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart, and brain. Orphanet J. Rare Dis. 2013, 8:47.
29. Weidemann F., Niemann M., Störk S., Breunig F., Beer M., Sommer C., Herrmann S., Ertl G., Wanner C. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J. Intern. Med. 2013, 274:1-13.
30. Alegra T., Vairo F., de Souza M., Krug B.C., Schwartz I.V.D. Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet. Mol. Biol. 2012, 35:947-954.
31. Nicholls K. Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry subjects. J. Inherit. Metab. Dis. 2012, 35:885-889.
32. Rombach S.M., van den Bogaard B., de Groot F., Groener J.E.M., Poorthuis B.J., Linthorst G.E., van den Born B.J.H., Hollak C.E.M., Aerts J.M.F.G. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012, 60:998-1005.
33. Ramasubbu K., Estep J., White D.L., Deswal A., Mann D.L. Experimental and clinical basis for the use of statins in subjects with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 2008, 51:415-426.
34. Probstfield J.L., O'Brien K.D. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am. J. Cardiol. 2010, 105:10A-20A.
35. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in subjects with type 2 diabetes. N. Engl. J. Med. 2003, 348:383-393.
36. Warnock D.G., Ortiz A., Mauer M., Linthorst G.E., Oliveira J.P., Serra A.L., Marodi L., Mignani R., Vujkovac B., Beitner-Johnson D., Lemay R., Cole J.A., Svarstad E., Waldek S., Germain D.P., Wanner C. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012, 27:1042-1049. on behalf of the Fabry Registry.